Pfizer Case Analysis

113
Case Analysis

Transcript of Pfizer Case Analysis

Page 1: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 1/113

Case

Analysis

Page 2: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 2/113

Analysis

CEO:

 Jefrey B. Kindler (2006 -2010)

Location: New York, USA (Corpor!e "ed#$r!er%)

Web Site Address: &!!p'www.p*er.+o

Stock Exchange Listings: New York S!o+k +&n/e ()

ondon (3)

$rone!

Swi%%

%! +!%

Page 3: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 3/113

 4&e "i%!ory o5*er

Page 4: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 4/113

1849 o$ndedC&rle%*er

Copny

186

ir%!

doe%!i+prod$+!ion o5!r!ri+ +id +re o5

!r!r

188!

Be/$n

prod$+!iono5 +i!ri+

+id

1891

7e!& o5C&rle%r&r!

 4&e "i%!ory o5 *er

Page 5: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 5/113

19!!

8fered%&re%o5

+oon %!o+k!o !&e

p$9li+

1919

S$++e%%5$llypioneered%%

prod$+!ion o5+i!ri+ +id5ro %$/r

198

Alenderlein/di%+o:ered

!&en!i9io!i+proper!ie%

o5

peni+illinold

19"6

7e:eloped5eren!!io

n 5reee!&od 5orprod$+in/%+or9i+

+id 

 4&e "i%!ory o5 *er

Page 6: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 6/113

 4&e "i%!ory o5 *er

Page 7: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 7/113

 4&e "i%!ory o5 *er

Page 8: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 8/113

 4&e "i%!ory o5 *er

Page 9: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 9/113

Key rod$+!%

Page 10: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 10/113

&r+e$!i+l%

Page 11: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 11/113

Crdio:%+$lr nd

;e!9oli+ 7i%e%e%

Page 12: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 12/113

Cen!rl Ner:o$% Sy%!e

7i%order%

Page 13: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 13/113

Ar!&ri!i% ndin

Urolo/y

8p&!&lolo/y

ndo+rine 7i%order

Page 14: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 14/113

<n5e+!io$% nd

=e%pir!ory 7i%e%e%

Page 15: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 15/113

8n+olo/y

Page 16: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 16/113

Anil "el!&

Page 17: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 17/113

Anil "el!&

Page 18: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 18/113

;i%%ion nd >i%ionS!!een!%

Page 19: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 19/113

?e dedi+!e o$r%el:e% !o

&$ni!y@% #$e%! 5or lon/er,&el!&ier, &ppier li:e% !&ro$/&inno:!ion in p&r+e$!i+l,+on%$er, nd nil &el!&

prod$+!%.

>i%ion

Page 20: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 20/113

?e will 9e+oe !&e world@% o%!

:l$ed +opny !o p!ien!%,+$%!oer%, +olle/$e%, in:e%!or%,9$%ine%% pr!ner%, nd !&e+o$ni!ie% w&ere we work nd

li:e.

;i%%ion

Page 21: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 21/113

<n!ernlA%%e%%en!

Page 22: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 22/113

inn+il Anly%i%

Page 23: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 23/113

Page 24: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 24/113

Page 25: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 25/113

Page 26: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 26/113

Page 27: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 27/113

Page 28: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 28/113

Page 29: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 29/113

Page 30: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 30/113

Page 31: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 31/113

Page 32: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 32/113

Page 33: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 33/113

inn+il C&r!%

2006 200 20010D,000

110,000

111,000

112,000

11E,000

11F,000

11G,000

116,000

11F,E

11G,26

111,1F

Assets #in $illions%

Page 34: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 34/113

inn+il C&r!%

2006 200 2000

10,000

20,000

E0,000

F0,000

G0,000

60,000

FE,FD

G0,2GGE,GD2

Liabilities #in $illions%

inn+il C&r!%

Page 35: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 35/113

inn+il C&r!%

2006 200A 200BCF1,000

CF2,000

CFE,000

CFF,000

CFG,000

CF6,000

CFA,000

CFB,000

CF6,DFDCF6,BFD

CFE,0A6

C&rrent Assets #in $illions%

inn+il C&r!%

Page 36: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 36/113

inn+il C&r!%

2006 200 2000

G,000

10,000

1G,000

20,000

2G,000

E0,000

21,ED 21,EG

2,00D

C&rrent Liabilities #in $illions%

Page 37: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 37/113

inn+il =!io%

1 2 E0.0

0.G

1.0

1.G

2.0

2.G

2.2 2.1

1.6

C&rrent 'atio

Page 38: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 38/113

Page 39: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 39/113

inn+il C&r!%

2006 200 2000

10,000

20,000

E0,000

F0,000

G0,000

60,000

0,000

0,000

1,EG6G,010

G,GG6

Stockholders* e+&ity #in $illions%

Page 40: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 40/113

inn+il =!io%

2006 200 200 2006 0 00.0

0.1

0.1

0.2

0.2

0.E

0.E

0.1

0.1

0.E

Long (er$ )ebt to E+&ity 'atio

Page 41: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 41/113

inn+il C&r!%

2006 200A 200BC10D,000

C110,000

C111,000

C112,000

C11E,000

C11F,000

C11G,000

C116,000

C11F,BEA

C11G,26B

C111,1FB

Assets #in $illions%

Page 42: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 42/113

inn+il C&r!%

2006 200 2000

G,000

10,000

1G,000

20,000

2G,000

1D,EE

,1FF ,10F

,et -nco$e #in $illions%

Page 43: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 43/113

inn+il =!io%

2006 200 200 2006 0 00.0

0.0

0.0

0.1

0.1

0.1

0.1

0.1

0.2

0.20.2

0.1 0.1

'O-

Page 44: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 44/113

inn+il C&r!%

2006 200 2000

10,000

20,000

E0,000

F0,000

G0,000

60,000

0,000

0,000

1,EG6G,010

G,GG6

Stockholders* e+&ity #in $illions%

Page 45: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 45/113

inn+il C&r!%

2006 200 2000

G,000

10,000

1G,000

20,000

2G,000

1D,EE

,1FF ,10F

,et -nco$e #in $illions%

Page 46: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 46/113

inn+il =!io%

2006 200 200 2006 0 00.0

0.1

0.1

0.2

0.2

0.E

0.E0.E

0.10.1

'OE

Page 47: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 47/113

;n/een! Anly%i%

Page 48: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 48/113

Page 49: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 49/113

Page 50: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 50/113

;rke!in/ Anly%i%

Page 51: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 51/113

C$rren! ;rke!%

Page 52: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 52/113

Page 53: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 53/113

?e will 9e re+o/ni*ed 5or ee!in/ !&e

di:er%e edi+l need% o5 p!ien!% in

er/in/ ;rke!% ro$nd !&e world inn inno:!i:e, %o+illy re%pon%i9le, nd+oer+illy :i9le nner.

>i%ion

 (er/in/ ;rke!%)

i i

Page 54: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 54/113

?e will H

7e:elop 9old nd inno:!i:e pr!ner%&ip%

=e+& p!ien!% we &:e ne:er re+&ed 9e5ore ro:ide edi+ine% nd %er:i+e% in n

ford9le nner

Be re+o/ni*ed in &:in/ !&e 9e%! !len! in

&el!&+re Be+oe ledin/ 9iop&r+e$!i+l

+opny in er/in/ ;rke!%

;i%%ion

 (er/in/ ;rke!%)

Page 55: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 55/113

=e%er+& nd7e:elopen!

=7 ili!i @

Page 56: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 56/113

=7 +ili!ie%@

o+!ion

Page 57: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 57/113

-+oer+e

Page 58: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 58/113

*er.+o

Page 59: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 59/113

S!ren/!&% nd?ekne%%e%

Page 60: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 60/113

8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e

world nd %pred o:er ore !&n G0 +o$n!rie%

+ellen! re%er+& nd de:elopen! (=7)+re!in/ inno:!i:e nd 9rek!&ro$/& prod$+!%

;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l+opnie% in+re%in/ 9rnd rep$!!ion

"% o:er 100,000 eployee% % pr! o5 !&e

or/ni*!ion

S!ron/ 9rnd ne nd re+ll /lo9lly

S!ren/!&%

Page 61: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 61/113

N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew

nd i!% rke!in/ in5r%!r$+!$re i% well e%!9li%&ed!&ro$/&o$! !&e world

 4&erpe$!i+ +o:er/e i% :ery lr/e nd !&einno:!i:e re%er+&er% re 9rodenin/ i! 5$r!&er

?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5prod$+!%

?ide rn/e o5 re 9ein/ worked, !&! in+l$de%&$n &el!&, nil &el!&, +$%!oer &el!&, nd+orpor!e /ro$p%

 <n:ol:ed in li+en%in/ /reeen!% wi!& diferen!+opnie% 5or +oll9or!i:e re%er+& work

S!ren/!&%

Page 62: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 62/113

 4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l

9rnd% en% lii!ed %+ope 5or rke! %&re /row!&

Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%!&el!&+re 5r$d o5 rke!in/ i!% dr$/ ille/lly

>ery lii!ed pene!r!ion o5 9iolo/i+% rke!

;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!&

o!&er p&r+e$!i+l% +n &l!er i!% /lo9l

pop$lri!y 8:errelin+e on !&e !$re rke! (U.S.) nd %ll

n$9er o5 di%!ri9$!or%

?ekne%%e%

Page 63: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 63/113

<rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0

per+en! o5 !&e dr$/% $nder pri+e +on!rol

<nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%eddr$/ reedie% nd e$en! !re!en! pln!%

+k o5 or inde#$!e %$9%idie% nd %+l in+en!i:e%

5or !&e ind$%!ry

<nde#$!e #$li!y !e%!in/ 5+ili!ie% 5or !&e re/$l!ory

$!&ori!ie%, w&i+& &:e ore dini%!r!i:e nd le%%!e+&ni+l +p9ili!ie% % re%$l!

ii!ed ei%%ion ri/&!%

?ekne%%e%

Page 64: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 64/113

<n!ernl +!or

:l$!ion (<);!ri

-nternal .actor E/al&ation 0atrix #-.E%

Page 65: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 65/113

-nternal .actor E/al&ation 0atrix #-.E%  

Strengths Weight Rating

Weighted

Score

1. 8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e world nd %pred o:er ore!&n G0 +o$n!rie%

0.0E F 0.12

2. +ellen! re%er+& nd de:elopen! (=7) +re!in/ inno:!i:e nd

9rek!&ro$/& prod$+!%0.0G E 0.1G

E. ;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l +opnie% in+re%in/ 9rndrep$!!ion

0.0 F 0.2

F. "% o:er 100,000 eployee% % pr! o5 !&e or/ni*!ion 0.0F E 0.12

G. S!ron/ 9rnd ne nd re+ll /lo9lly 0.0 E 0.21

6. N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew nd i!% rke!in/in5r%!r$+!$re i% well e%!9li%&ed !&ro$/&o$! !&e world

0.0G F 0.20

. 4&erpe$!i+ +o:er/e i% :ery lr/e nd !&e inno:!i:e re%er+&er% re9rodenin/ i! 5$r!&er

0.0E E 0.0D

. ?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5 prod$+!% 0.0G E 0.1GD. ?ide rn/e o5 re 9ein/ worked, !&! in+l$de% &$n &el!&, nil &el!&,

+$%!oer &el!&, nd +orpor!e /ro$p%0.0F F 0.16

10. <n:ol:ed in li+en%in/ /reeen!% wi!& diferen! +opnie% 5or +oll9or!i:ere%er+& work 0.0 E 0.21

  Weaknesses Weight 'atingWeighted Score

1. 4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l 9rnd% en% lii!ed %+ope5or rke! %&re /row!& 0.0 2 0.16

2. Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%! &el!&+re 5r$d o5rke!in/ i!% dr$/ ille/lly

0.0G 2 0.10

E. >ery lii!ed pene!r!ion o5 9iolo/i+% rke! 0.0D 2 0.1

F. ;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!& o!&er p&r+e$!i+l% +n&l!er i!% /lo9l pop$lri!y

0.0G E 0.1G

G. 8:errelin+e on !&e !$re rke! (U.S.) nd %ll n$9er o5 di%!ri9$!or% 0.02 2 0.0F

6. <rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0 per+en! o5 !&e dr$/% $nder pri+e

+on!rol

0.0E F 0.12

. <nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%ed dr$/ reedie% nd e$en!0.0F E 0.12

Page 66: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 66/113

!ernlA%%e%%en!

Page 67: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 67/113

Cope!i!i:e or+e%

Page 68: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 68/113

Cope!i!or%

0erck 2 Co

- >++ine%

 - re%+rip!ion 7r$/% - Con%$er rod$+!%

 - Anil "el!&

S!r!e/ie%'• ;er/er% nd A+#$i%i!ion%• rod$+! 7e:elopen!• ;rke! 7e:elopen!• r!ner%&ip%

Page 69: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 69/113

Cope!i!or%

3ayer A

 - Byer "el!&Cre

- Byer CropS+ien+e

- Byer ;!erilS+ien+e

S!r!e/ie%'• Corpor!e So+il =e%pon%i9ili!y• Unrel!ed 7i:er%i+!ion• ;er/er% nd A+#$i%i!ion%• rod$+! 7e:elopen!

Page 70: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 70/113

Cope!i!or%

,o/artis A

 - &r+e$!i+l

 - Al+on L ye +re- Sndo* L Meneri+%

- 8:er-!&e-+o$n!er

S!r!e/ie%'• rod$+! 7e:elopen!• =el!ed 7i:er%i+!ion• ;er/er% nd A+#$i%i!ion%

Page 71: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 71/113

Cope!i!i:e role;!ri (C;)

C;

Page 72: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 72/113

Competitive Profile Matrix (CPM)

  PFIZER NOVARTIS MERCK Co. BAYER

Critical Success FactorsWeigh

tRating Score Rating Score Rating Score Rating Score

Advertising 0.05 4 0.20 3 0.15 3 0.15 3 0.15

Market Penetration 0.10 3 0.30 3 0.30 4 0.40 3 0.30

Customer Service 0.09 4 0.36 2 0.18 4 0.36 3 0.27

Store Locations 0.04 4 0.16 2 0.08 3 0.12 2 0.08

R&D 0.14 3 0.42 4 0.56 4 0.56 3 0.42

Employee Dedication 0.09 3 0.27 2 0.18 4 0.36 3 0.27

Financial Profit 0.10 4 0.40 4 0.40 2 0.20 4 0.40

Customer Loyalty 0.06 3 0.18 2 0.12 3 0.18 3 0.18

Market Share 0.10 4 0.40 3 0.30 2 0.20 2 0.20Product Quality 0.09 3 0.27 3 0.27 3 0.27 3 0.27

Top Management 0.05 3 0.15 3 0.15 2 0.10 2 0.10

Price Competitiveness 0.09 3 0.27 4 0.36 3 0.27 3 0.27

Totals 1.00 3.38 3.05 3.17 2.91

C;

Page 73: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 73/113

+onoi+ <%%$e%

U S +onoy

Page 74: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 74/113

*er %$fered 5ro %lowdown in %le% 5!er

ny o5 i!% dr$/% wen! of p!en! nd /eneri+-dr$/ +opnie% po+&ed %le%. 4&e dr$/ker w% 5or+ed !o +$! =7 %pendin/ ndpre !&e %i*e o5 i!% %le% 5or+e in 200.

U.S. +onoy

=e+e%%ion

Page 75: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 75/113

ropo%ed A+#$i%i!iono5 ?ye!&

Page 76: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 76/113

o!en!il Bene!%

Page 77: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 77/113

8ppor!$ni!ie% nd 4&re!%

Page 78: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 78/113

S!r!e/i+ /reeen!% wi!& o!&er

p&r+e$!i+l +opnie% ndor/ni*!ion% !o 9oo%! i!% re%er+&.

<n+re%in/ wrene%% o5 people 9o$! !&eir&el!&+re need%

Mlo9l pene!r!ion !&ro$/& er/er% nd

+#$i%i!ion% <n+re%in/ dend 5or #$li!y &el!&+re

%ol$!ion%

=e%!r$+!$rin/ %!r!e/y de%i/ned !o +$!

+o%!% nd lener +opny

8ppor!$ni!ie%

Page 79: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 79/113

$ndin/ :il9le !o 5+ili!!e

prod$+!+opny

A+#$i%i!ion% (?ye!&) nd in-li+en%in/+o-de:elopen! oppor!$ni!ie%

pn%ion in!o 9iolo/i+% rke!

-Coer+e

"i/& pro!%, re:en$e% nd 5$nd% re:il9le !o $pli5! !&e +opny% pro/re%%

8ppor!$ni!ie%

Page 80: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 80/113

=i%k o5 $n%$++e%%5$l new prod$+!%

=e/$l!ory en:ironen! i% 9e+oin/

ore ore %!rin/en! +onoi+ %lowdown in $ropen

rke!%

<n+re%ed rke! +ope!i!ion%

o%in/ o5 p!en! indi:id$li!y 9y5o+$%in/ on one prod$+!

 4&re!%

Page 81: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 81/113

o%% o5 p!en! pro!e+!ion o5 or prod$+!%

=i%k o5 i%i !erin!in/ lon/-%!ndin/

pr!ner%&ip 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!%

lon/ wi!& eer/in/ rke!% o5 <ndi ndC&in

Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir+$%!oer%

"el!&+re re5or in !&e US fe+!% re:en$e/row!&

 4&re!%

Page 82: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 82/113

!ernl +!or

:l$!ion ();!ri

  External .actor E/al&ation 0atrix #E.E%  

Page 83: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 83/113

O55ort&nities Weight 'atingWeighted Score

1. S!r!e/i+ /reeen!% wi!& o!&er p&r+e$!i+l +opnie% nd or/ni*!ion% !o9oo%! i!% re%er+&.

0.0D E 0.2

2. <n+re%in/ wrene%% 9o$! &el!&+re need% 0.06 E 0.1

E. Mlo9l pene!r!ion !&ro$/& er/er% nd +#$i%i!ion% 0.0 F 0.2F. <n+re%in/ dend 5or #$li!y &el!&+re %ol$!ion% 0.0 E 0.21

G. =e%!r$+!$rin/ %!r!e/y de%i/ned !o +$! +o%!% nd lener +opny 0.0E E 0.0D

6. $ndin/ :il9le !o 5+ili!!e prod$+!+opny 0.02 E 0.06

. A+#$i%i!ion% (?ye!&) nd in-li+en%in/+o-de:elopen! oppor!$ni!ie% 0.0 F 0.2

. pn%ion in!o 9iolo/i+% rke! 0.0G E 0.1G

D. -Coer+e 0.0E 2 0.06

10. "i/& pro!%, re:en$e% nd 5$nd% re :il9le !o $pli5! !&e +opny% pro/re%% 0.0F F 0.16

  (hreats Weight 'atingWeighted Score

1. =i%k o5 $n%$++e%%5$l new prod$+!% 0.0F 2 0.0

2. =e/$l!ory en:ironen! i% 9e+oin/ ore ore %!rin/en! 0.0G E 0.1G

E. +onoi+ %lowdown in $ropen rke!% 0.0E 2 0.06

F. <n+re%ed rke! +ope!i!ion% 0.06 E 0.1

G. o%in/ o5 p!en! indi:id$li!y 9y 5o+$%in/ on one prod$+! 0.0 E 0.2F

6. o%% o5 p!en! pro!e+!ion o5 or prod$+!% 0.0 F 0.2. =i%k o5 i%i !erin!in/ lon/-%!ndin/ pr!ner%&ip 0.0F E 0.12

. 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!% lon/ wi!& eer/in/ rke!% o5<ndi nd C&in

0.0E 2 0.06

D. Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir +$%!oer% 0.0F F 0.16

10. "el!&+re re5or in !&e US fe+!% re:en$e /row!& 0.0E E 0.0D

  (O(ALS 1!!   88

Page 84: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 84/113

S!r!e/yor$l!ion

Page 85: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 85/113

S?84 ;!ri

Page 86: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 86/113

1. 8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e world nd %predo:er ore !&n G0 +o$n!rie%

2. +ellen! re%er+& nd de:elopen! (=7) +re!in/ inno:!i:e nd9rek!&ro$/& prod$+!%

E. ;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l +opnie%in+re%in/ 9rnd rep$!!ion

F. "% o:er 100,000 eployee% % pr! o5 !&e or/ni*!ion

G. S!ron/ 9rnd ne nd re+ll /lo9lly

6. N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew nd i!%rke!in/ in5r%!r$+!$re i% well e%!9li%&ed !&ro$/&o$! !&e world

.  4&erpe$!i+ +o:er/e i% :ery lr/e nd !&e inno:!i:e re%er+&er% re9rodenin/ i! 5$r!&er

. ?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5 prod$+!%

D. ?ide rn/e o5 re 9ein/ worked, !&! in+l$de% &$n &el!&, nil&el!&, +$%!oer &el!&, nd +orpor!e /ro$p%

10.  <n:ol:ed in li+en%in/ /reeen!% wi!& diferen! +opnie% 5or

+oll9or!i:e re%er+& work

S!ren/!&%

Page 87: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 87/113

1.  4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l 9rnd% en%

lii!ed %+ope 5or rke! %&re /row!&

2. Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%! &el!&+re 5r$do5 rke!in/ i!% dr$/ ille/lly

E. >ery lii!ed pene!r!ion o5 9iolo/i+% rke!

F. ;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!& o!&erp&r+e$!i+l% +n &l!er i!% /lo9l pop$lri!y

G. 8:errelin+e on !&e !$re rke! (U.S.) nd %ll n$9er o5di%!ri9$!or%

6. <rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0 per+en! o5 !&e dr$/%

$nder pri+e +on!rol. <nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%ed dr$/ reedie% nd

e$en! !re!en! pln!%

. +k o5 or inde#$!e %$9%idie% nd %+l in+en!i:e% 5or !&e ind$%!ry

D. <nde#$!e #$li!y !e%!in/ 5+ili!ie% 5or !&e re/$l!ory $!&ori!ie%,w&i+& &:e ore dini%!r!i:e nd le%% !e+&ni+l +p9ili!ie% %

re%$l!

?ekne%%e%

Page 88: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 88/113

1. S!r!e/i+ /reeen!% wi!& o!&er p&r+e$!i+l +opnie% nd

or/ni*!ion% !o 9oo%! i!% re%er+&.

2. <n+re%in/ wrene%% 9o$! &el!&+re need%

E. Mlo9l pene!r!ion !&ro$/& er/er% nd +#$i%i!ion%F. <n+re%in/ dend 5or #$li!y &el!&+re %ol$!ion%

G. =e%!r$+!$rin/ %!r!e/y de%i/ned !o +$! +o%!% nd lener +opny

6. $ndin/ :il9le !o 5+ili!!e prod$+!+opny

. A+#$i%i!ion% nd in-li+en%in/+o-de:elopen! oppor!$ni!ie%

. pn%ion in!o 9iolo/i+% rke!

D. -Coer+e

10."i/& pro!%, re:en$e% nd 5$nd% re :il9le !o $pli5! !&e+opny% pro/re%%

8ppor!$ni!ie%

Page 89: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 89/113

1. =i%k o5 $n%$++e%%5$l new prod$+!%

2. =e/$l!ory en:ironen! i% 9e+oin/ ore ore %!rin/en!

E. +onoi+ %lowdown in $ropen rke!%

F. <n+re%ed rke! +ope!i!ion%G. o%in/ o5 p!en! indi:id$li!y 9y 5o+$%in/ on one prod$+!

6. o%% o5 p!en! pro!e+!ion o5 or prod$+!%

. =i%k o5 i%i !erin!in/ lon/-%!ndin/ pr!ner%&ip

. 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!% lon/ wi!&

eer/in/ rke!% o5 <ndi nd C&inD. Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir +$%!oer%

10."el!&+re re5or in !&e US fe+!% re:en$e /row!&

 4&re!%

Page 90: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 90/113

<! +n $%e i!% rep$!!ion % one o5 !&e lr/e%!

p&r+e$!i+l +opny in !&e world !o /in

%!r!e/i+ /reeen!% wi!& o!&er +opnie%nd or/ni*!ion% !o 9oo%! i!% re%er+& (S1,81)

<! +n $%e i!% 5$lly in!e/r!ed n$5+!$rin/5+ili!ie% !o epnd in!o !&e 9iolo/i+% rke!

(S10, 8)

<! +n $%e i!% rke!in/ in5r%!r$+!$re !o &:e rke!in/ /reeen!% wi!& ledin/+opnie% (S6 810)

S8 S!r!e/ie%

Page 91: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 91/113

<! +n $%e i!% e+ellen! re%er+& nd

de:elopen! (=7) pro/r !o red$+e !&e

!&re!% or $n%$++e%%5$l new prod$+!% (S2 41) <! +n $%e i!% er/er% nd +#$i%i!ion%%!r!e/ie% !o red$+e !&e in+re%in/ rke!+ope!i!ion (SE 4F)

<!% %!ron/ 9rnd ne nd re+ll /lo9lly +nred$+e !&e !&re!% /i:en 9y in+re%in/ en!rie%o5 pri:!e indi:id$l% (SG 4D)

S4 S!r!e/ie%

Page 92: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 92/113

Page 93: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 93/113

Allo+!e 5$r!&er re%er+& efor!% 9e5ore new

ind$+!ion% in !&e rke! (?6 41)

$nd +pi!l ependi!$re% on in5r%!r$+!$re%5or 5eren!!ion-9%ed dr$/ reedie% nde$en! !re!en! pln!% (? 41)

ro:ide dded rke!in/ efor!% !o re/in n++ep!9le p$9li+ i/e 5or pre:io$%ly %$edprod$+!% (?1 4)

?4 S!r!e/ie%

Page 94: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 94/113

SAC ;!ri

SAC ;!ri

Page 95: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 95/113

FINANCIAL POSITION STABILITY POSITION

Return on Investment (ROI) 3 Rate of Inflation -

Levera!e " Te#$nolo!i#al C$an!es -3

Li%ui&it' Pri#e lasti#it' of *eman& -

+or,in! Caital Cometitive Pressure -

Cas$ Flo. Barriers to ntr' into /ar,et -3 

Financial Position (FP) Average 4.6 Stability Position (SP) Average -3.6

CO/PTITI0 POSITION IN*1STRY POSITION

/ar,et S$are -2 ro.t$ Potential

Pro&u#t 4ualit' -3 Finan#ial Sta5ilit' 3

Customer Lo'alt' -2 ase of ntr' into /ar,et

Te#$nolo!i#al ,no.-$o. - Resour#e 1tili6ation

Control over Suliers an& -2 Profit Potential

SAC ;!ri

 

 Con%er:!i:e A//re%%i:e

7

Page 96: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 96/113

7axis  14  

6 axis  1!  

G

F

E

2

1

C - -6 -G -F -E -2 -1 1 2 E F G 6 <  -1

-2

-E

-F

-G

-6

-7e5en%i:e S   Cope!i!i:e

7 <n!e/r!ionS!r!e/ie%7 ;rke! ene!r!ion7 ;rke! 7e:elopen!7 7i:er%i+!ion

S!r!e/ie%

Page 97: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 97/113

BCM ;!ri

BCM ;A4=<O

Page 98: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 98/113

*ivision 5' eo!ra$i# Area

#S International

Pro$its 8932"92:9::: 2:9:;9:::9:::

%even!es 2:939:::9::: 2<9="89:::9:::

BCM ;A4=<O

Relative Market Share Position

 High Medium

Page 99: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 99/113

 Low

High+20

1.0 .50

0.0

S!r P$e%!ion ;rk

 

Medium

0  

C%& Cow 7o/ 

<n!ern!ionl

US

BCM ;A4=<O

Page 100: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 100/113

BCM ;A4=<O

7i:i%ion 9y B$%ine%% Se/en!

&r+e$!i+l% Anil &el!& Corpor!e8!&er

ro;ts EG,EED,200,000 2,11,G0,000 ,200,000

'e/en&es FF,1F,000,000 2,2G,000,000 1,2D,000,000

Page 101: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 101/113

Relative Market Share Position

 High Medium Low

High+20 1.0 .50 0.0

S!r P$e%!ion ;rk

 

Medium 0  

C%& Cow 7o/ 

Corpor!e

Anil "el!&

&r+e$!i+

l%

Page 102: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 102/113

<n!ernl-!ernl;!ri

(he (otal -.E Weighted Scores

S!ron/ A:er/e ?ek

Page 103: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 103/113

S!ron/ A:er/e ?ek

F.0 !o E.0 2.DD !o 2.0 1.DD !o 1.0F.0 < << <<<

 

"i/&

E.0 <> > >< 

*er

< L E.06 L E.0 ro< and 3&ild

7 <n!e/r!ion S!r!e/ie%7 <n!en%i:e S!r!e/ie%

Page 104: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 104/113

Mrnd S!r!e/y;!ri

 =pid ;rke! Mrow!&

 

Page 105: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 105/113

P$drn! << P$drn! <

?ekCope!i!i:e

o%i!ion

 S!ron/

Cope!i!i:eo%i!ion

 

P$drn! <<< P$drn! <>

Slow ;rke! Mrow!&  

*er

7 <n!e/r!ionS!r!e/ie%

7 <n!en%i:e S!r!e/ie%7 =el!ed

7i:er%i+!ion

P !i! !i

Page 106: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 106/113

P$n!i!!i:e

S!r!e/i+ lnnin/;!ri

Page 107: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 107/113

Page 108: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 108/113

Page 109: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 109/113

=e+oend!ion%

= d !i

Page 110: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 110/113

 4&ere5ore we re+oend !&e +opny !o +on!in$e

in +#$irin/ ?ye!& 5or i! &% !&e &i/&e%! %$ o5 !o!lAl!ern!i:e %+ore o5 6.F1.

Sin+e !&e p!en! o5 i%i@% Ari+ep! will epire on 2010!&e +opny need !o in+re%e i!% 5$nd% in re%er+&

nd de:elopen! %o !&! i! +n de:elop newprod$+!% !o +$re di%e%e%.

B$! %in+e *er 5$nd 5or re%er+& nd de:elopen! i%no! !&! &i/&, i! i% 9e!!er !o +#$ire %ll +opny

r%! !o in+re%e ore %le% 9e5ore !&e +opny +nin+re%e i!% re%er+& nd de:elopen! 5$nd%.

=e+oend!ion

Page 111: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 111/113

S!r!e/y<pleen!!ion

! !i l =i k

Page 112: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 112/113

=e/$l!ory "$rdle%

<n+re%e% *er@% de9!%

A%%$p!ion o5 i!i/!ion% o5 ?ye!& Co%! +$!!in/ nd y-of%

o!en!il =i%k%

Page 113: Pfizer Case Analysis

7/25/2019 Pfizer Case Analysis

http://slidepdf.com/reader/full/pfizer-case-analysis 113/113

nd